经济观察网泰恩康（301263）2026年将有多项关键事件值得关注，涉及公司治理、产品管线及市场动 态。 公司多个仿制药和创新药预计在2026年取得重要进展。复方硫酸钠片(国内首仿)与和胃整肠丸(国内独 家)的本地化生产注册均预计在2026年上半年获批。老花眼用药盐酸毛果芸香碱滴眼液(国内首仿)预计在 2026年下半年获批。此外，创新药CKBA乳膏针对儿童白癜风的II期临床试验计划于2026年第一季度启 动首例患者入组，并计划同期向FDA申报。 股票近期走势 2026年1月28日，公司发布《2026年员工持股计划(草案)》，拟向不超过145名员工实施股权激励，并设 定了2026年至2028年的业绩考核目标。其中，2026年营业收入目标值为10.00亿元，考核利润目标值为 3.00亿元。 产品研发进展 公司于2025年12月15日被纳入中证1000指数拟生效样本范围，市场预期其有望被纳入相关ETF的被动配 置范畴，可能对股票流动性产生长期影响。2026年2月2日，公司控股股东郑汉杰和孙伟文部分股份质 押，合计质押股份占公司总股本的13.81%，公告称此举为个人资金需要。2026年2月13日，泰恩康股价 上涨2. ...

深圳市深南大道 6008 号特区报业大厦 24、31、41、42 楼 邮编：518034 24/F、31/F、41/F、42/F, Tequbaoye Building, 6008 Shennan Avenue, Shenzhen, Guangdong Province 518034, China 电话/Tel: (+86)(755) 8351 5666 传真/Fax: (+86)(755) 8351 5333 网址/Website: http://www.grandall.com.cn 二〇二六年二月 | | | 国浩律师（深圳）事务所 关于 广东泰恩康医药股份有限公司 2026 年员工持股计划 之 法律意见书 | 目 | 录 I | | --- | --- | | 释 | 义 I | | | 八、结论意见 9 | 释 义 除非另有说明，本法律意见书中相关词语具有以下特定含义： 简称 指 全称 泰恩康、公司、上市公司 指 广东泰恩康医药股份有限公司 本次员工持股计划、本员工 持股计划、本计划 指 广东泰恩康医药股份有限公司2026年员工持股计划 《员工持股计划（草案）》 指 《广东泰恩康医药股份有限公司20 ...

Core Viewpoint - The announcement highlights that Tiancon (301263) has received a drug registration certificate for Minoxidil topical solution from the National Medical Products Administration, indicating a significant step in the company's product development and market entry in the hair loss treatment sector [1] Company Summary - Tiancon's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has been granted the registration certificate for Minoxidil topical solution, with acceptance numbers CYHS2400976 and CYHS2400977 [1] - The registered product is classified as a Class 3 chemical drug, with specifications of 60ml:1.2g and 60ml:3.0g, and the approval numbers are 国药准字H20263325 and 国药准字H20263326 [1] - The approval conclusion states that the product meets the registration requirements, allowing for its market introduction [1] Industry Summary - Minoxidil is recognized as a topical treatment for hair loss, and the company anticipates growth in the domestic hair loss treatment market due to the rising prevalence of hair loss conditions [1]

Group 1 - The core announcement is that Tianenkang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [2] Group 2 - The approval of the Minoxidil lotion indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical market [2] - This development may open new avenues for revenue generation and market expansion for the company in the biopharmaceutical sector [2]

Group 1 - The core point of the article is that Guangdong Tianen Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [1] Group 2 - The product name is "Minoxidil lotion" [1]

Core Viewpoint - The company TianKang's wholly-owned subsidiary, Huabo Kaisheng, has received a drug registration certificate for Minoxidil topical solution from the National Medical Products Administration, indicating a significant step in the company's product development and market entry in the hair loss treatment sector [1] Company Summary - TianKang's subsidiary has been granted a registration certificate for Minoxidil topical solution, classified as a Class 3 chemical drug, with specifications of 60ml: 1.2g and 60ml: 3.0g [1] - The approval numbers for the drug are Guoyao Zhunzi H20263325 and Guoyao Zhunzi H20263326 [1] Industry Summary - Minoxidil is a commonly used topical treatment for hair loss, and the domestic market for hair loss treatments is expected to grow [1] - Currently, there are 31 companies that have received registration approvals for this drug in the domestic market, indicating a competitive landscape [1] - The future sales performance of the product will be influenced by industry policies and market conditions, which introduces a level of uncertainty [1]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, a commonly used treatment for hair loss [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), is responsible for the registration of Minoxidil [1] - The approval of Minoxidil is expected to enhance the company's product portfolio in the hair loss treatment market [1] Group 2: Industry Insights - Minoxidil is a well-known topical treatment for hair loss, functioning as a vasodilator that relaxes blood vessel walls, facilitating blood flow to the scalp and hair follicles [1] - The drug works by catalyzing the formation of the active metabolite Minoxidil sulfate, which stimulates hair follicle growth and promotes the proliferation of atrophied hair follicles [1]

Core Viewpoint - The announcement indicates that TianKang's wholly-owned subsidiary, Huabo Kaisheng, has received drug registration certificates for Minoxidil topical solution from the National Medical Products Administration, marking a significant step in the company's product offerings in the hair loss treatment market [1] Group 1: Company Developments - Huabo Kaisheng has been granted registration for Minoxidil topical solution in two formulations: 60ml:1.2g and 60ml:3.0g, with approval numbers H20263325 and H20263326 respectively [1] - The product's sales performance is subject to various influencing factors, indicating potential variability in market reception and revenue generation [1] Group 2: Industry Insights - The domestic market for hair loss prevention is projected to grow, with 31 companies currently holding registration for Minoxidil topical solution in China, highlighting a competitive landscape [1]

证券代码：301263 证券简称：泰恩康 公告编号：2026-012 受理号：CYHS2400976、CYHS2400977 药品名称：米诺地尔搽剂 申请事项：境内生产药品注册上市许可 许可药品注册分类：化学药品 3 类 广东泰恩康医药股份有限公司 关于全资子公司收到米诺地尔搽剂 药品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司山东华铂 凯盛生物科技有限公司（以下简称"华铂凯盛"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）签发的米诺地尔搽剂《药品注册证书》。现 将相关情况公告如下： 一、申请注册药品的基本情况 规格：60ml：1.2g；60ml：3.0g 药品批准文号：国药准字 H20263325、国药准字 H20263326 申请人：山东华铂凯盛生物科技有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品相关情况简介 米诺地尔是目前常用的外用脱发治疗药物，作为地尔类血管扩张药，可使 血 ...